A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
paper
Cited
Public
Unavailable
- Authors
- Bloch, M H; Landeros-Weisenberger, A; Kelmendi, B; Coric, V; Bracken, M B; Leckman, J F
- Year
- 2006
- Journal
- Molecular psychiatry
- PMID
- 16585942
- DOI
- 10.1038/sj.mp.4001823
As many as half of obsessive-compulsive disorder (OCD) patients treated with an adequate trial of serotonin reuptake inhibitors (SRIs) fail to fully respond to treatment and continue to exhibit significant symptoms. Many studies have assessed the effectiveness of antipsychotic augmentation in SRI-refractory OCD. In this systematic review, we evaluate the efficacy of antipsychotic augmentation in treatment-refractory OCD. The electronic databases of PubMed, PsychINFO (1967-2005), Embase (1974-2000) and the Cochrane Central Register of Controlled Trials (CENTRAL, as of 2005, Issue 3) were searched for relevant double-blind trials using keywords 'antipsychotic agents' or 'neuroleptics' and 'obsessive-compulsive disorder'. Search results and analysis were limited to double-blind, randomized control trials involving the adult population. The proportion of subjects designated as treatment responders was defined by a greater than 35% reduction in Yale Brown Obsessive-Compulsive Scale (Y-BOCS) rating during the course of augmentation therapy. Nine studies involving 278 participants were included in the analysis. The meta-analysis of these studies demonstrated a significant absolute risk difference (ARD) in favor of antipsychotic augmentation of 0.22 (95% confidence interval (CI): 0.13, 0.31). The subgroup of OCD patients with comorbid tics have a particularly beneficial response to this intervention, ARD=0.43 (95% CI: 0.19, 0.68). There was also evidence suggesting OCD patients should be treated with at least 3 months of maximal-tolerated therapy of an SRI before initiating antipsychotic augmentation owing to the high rate of treatment response to continued SRI monotherapy (25.6%). Antipsychotic augmentation in SRI-refractory OCD is indicated in patients who have been treated for at least 3 months of maximal-tolerated therapy of an SRI. Unfortunately, only one-third of treatment-refractory OCD patients show a meaningful treatment response to antipsychotic augmentation. There is sufficient evidence in the published literature, demonstrating the efficacy of haloperidol and risperidone, and evidence regarding the efficacy of quetiapine and olanzapine is inconclusive. Patients with comorbid tics are likely to have a differential benefit to antipsychotic augmentation.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. | 2015 | 25158072 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Case Series on Obsessive-compulsive Disorder in Twins: Phenotypic Divergence and Shared Therapeutic Challenges. | Chouhan A et al. | β | 2026 | β |
| Clinical predictors of treatment resistance to serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. | Balachander S et al. | β | 2026 | β |
| Tics and Tic-Like Phenomena as Compulsive Acts. | Grippe T et al. | β | 2026 | β |
| Behavioral disorders in multiple sclerosis: a comprehensive review. | Jellinger KA | β | 2025 | β |
| Disruption of consciousness depends on insight in obsessive-compulsive disorder and on positive symptoms in schizophrenia. | Tumkaya S et al. | β | 2025 | β |
| High Doses of Antidepressants and Long-term Treatment of Obsessive-compulsive Disorder: Another Barrier to Accessing Deep Brain Stimulation? | Verstraete E et al. | β | 2025 | β |
| Innovative treatment approaches for paediatric obsessive-compulsive disorder. | Marazziti D et al. | β | 2025 | β |
| Medication adherence in obsessive-compulsive disorders and evaluation of effective adherence support strategies. | PΓΆppel S et al. | β | 2025 | β |
| National Trends in Pediatric Obsessive compulsive disorder Management: Insights from a Retrospective Cohort Study. | Baweja R et al. | β | 2025 | β |
| Obsessive-compulsive disorder - A state-of-the-art review. | Endres D et al. | β | 2025 | β |
| Peripheral Blood Biomarkers Reveal Dysregulated Monoaminergic Pathways in Obsessive-Compulsive Disorder: A Transcriptional and Epigenetic Analysis. | Bellia F et al. | β | 2025 | β |
| Pharmacotherapy for Tourette Syndrome. | Jurgen BO et al. | β | 2025 | β |
| Psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: protocol for an open-label pilot study. | Ledwos N et al. | β | 2025 | β |
| A biophysical model for dopamine modulating working memory through reward system in obsessive-compulsive disorder. | Yin L et al. | β | 2024 | β |
| An evaluation of treatment response and remission definitions in adult obsessive-compulsive disorder: A systematic review and individual-patient data meta-analysis. | Ramakrishnan D et al. | β | 2024 | β |
| Cognitive and clinical predictors of a long-term course in obsessive compulsive disorder: A machine learning approach in a prospective cohort study. | SegalΓ s C et al. | β | 2024 | β |
| Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part I. | Cortese S et al. | β | 2024 | β |
| Disruption of consciousness depends on insight in OCD and on positive symptoms in schizophrenia | Tumkaya S et al. | β | 2024 | β |
| Early-onset obsessive-compulsive disorder: Sociodemographic and clinical characterization of a large outpatient cohort. | Girone N et al. | β | 2024 | β |
| Pediatric Treatment-Resistant Obsessive Compulsive Disorder: Treatment Options and Challenges. | Younus S et al. | β | 2024 | β |
| Pharmacotherapy for obsessive-compulsive disorder: Real-world evidence from a 10-year retrospective data analysis. | Oh S et al. | β | 2024 | β |
| Antipsychotics and obsessive-compulsive disorder/obsessive-compulsive symptoms: A pharmacovigilance study of the FDA adverse event reporting system. | Burk BG et al. | β | 2023 | β |
| Common practical questions - and answers - at the British Association for Psychopharmacology child and adolescent psychopharmacology course. | Cortese S et al. | β | 2023 | β |
| Co-Occurring Anxiety in Youth with Tic Disorders: A Review. | Sapozhnikov Y et al. | β | 2023 | β |
| Neurofeedback for obsessive compulsive disorder: A randomized, double-blind trial. | Rance M et al. | β | 2023 | β |
| Obsessive-Compulsive, Psychotic, and Autism Dimensions Overlap in Real World: A Case Report. | Scala M et al. | β | 2023 | β |
| The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia. | Vellucci L et al. | β | 2023 | β |
| The Pharmacological Treatment of Obsessive-Compulsive Disorder. | Pittenger C | β | 2023 | β |
| The Sapap3<sup>-/-</sup> mouse reconsidered as a comorbid model expressing a spectrum of pathological repetitive behaviours. | Lamothe H et al. | β | 2023 | β |
| Treatment strategies for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: A network meta-analysis of randomised controlled trials. | Suhas S et al. | β | 2023 | β |
| An overview of the pharmacological options for pediatric obsessive-compulsive disorder. | Marazziti D et al. | β | 2022 | β |
| Current and emerging pharmacotherapeutic strategies for Tourette syndrome. | Cavanna AE | β | 2022 | β |
| Deep brain stimulation for treatment-refractory obsessive-compulsive disorder should be an accepted therapy in Australia. | Mosley PE et al. | β | 2022 | β |
| Developmental impact of glutamate transporter overexpression on dopaminergic neuron activity and stereotypic behavior. | Chohan MO et al. | β | 2022 | β |
| European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. | Roessner V et al. | β | 2022 | β |
| Granisetron-mediated augmentation of sertraline therapeutic effect in obsessive-compulsive disorder: a double-blind placebo-controlled, randomized clinical trial. | Ghobadian A et al. | β | 2022 | β |
| Heart rate variability in obsessive compulsive disorder in comparison to healthy controls and as predictor of treatment response. | Olbrich H et al. | β | 2022 | β |
| InvestΔ±gation of vitamin D levels in obsessive-compulsive disorder. | Soyak HM et al. | β | 2022 | β |
| Moving beyond first-line treatment options for OCD. | Paxos C | β | 2022 | β |
| The prefrontal cortex and OCD. | Ahmari SE et al. | β | 2022 | β |
| An integrated program of computer-presented and physical cognitive training exercises for children with attention-deficit/hyperactivity disorder. | Wexler BE et al. | β | 2021 | β |
| Anxiety Symptoms Differ in Youth With and Without Tic Disorders. | Vermilion J et al. | β | 2021 | β |
| A randomised, double-blind, sham-controlled trial of deep brain stimulation of the bed nucleus of the stria terminalis for treatment-resistant obsessive-compulsive disorder. | Mosley PE et al. | β | 2021 | β |
| Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder. | Goodman WK et al. | β | 2021 | β |
| Inflammation, Obsessive-Compulsive Disorder, and Related Disorders. | Meyer J | β | 2021 | β |
| Neuropsychiatric effects of subthalamic deep brain stimulation. | Mosley PE et al. | β | 2021 | β |
| NOX1/NADPH Oxidase Promotes Synaptic Facilitation Induced by Repeated D<sub>2</sub> Receptor Stimulation: Involvement in Behavioral Repetition. | Asaoka N et al. | β | 2021 | β |
| Obsessive-Compulsive Disorders. | Mathews C | β | 2021 | β |
| Pharmacotherapeutic Strategies and New Targets in OCD. | Pittenger C | β | 2021 | β |
| Specialty knowledge and competency standards for pharmacotherapy for adult obsessive-compulsive disorder. | Pittenger C et al. | β | 2021 | β |
| Specialty knowledge and competency standards for pharmacotherapy for pediatric obsessive-compulsive disorder. | Weidle B et al. | β | 2021 | β |
| Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder. | Shephard E et al. | β | 2021 | β |
| Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. | Fineberg NA et al. | β | 2020 | β |
| Large nest building and high marble-burying: Two compulsive-like phenotypes expressed by deer mice (Peromyscus maniculatus bairdii) and their unique response to serotoninergic and dopamine modulating intervention. | de Brouwer G et al. | β | 2020 | β |
| Lifetime bipolar disorder comorbidity and related clinical characteristics in patients with primary obsessive compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). | Dell'Osso B et al. | β | 2020 | β |
| Marble-burying behavior test as a murine model of compulsive-like behavior. | Dixit PV et al. | β | 2020 | β |
| Paliperidone in Obsessive-Compulsive Disorder: A Case Study. | Panthee P et al. | β | 2020 | β |
| Pharmacotherapy for Treatment-Resistant Obsessive-Compulsive Disorder. | Kayser RR | β | 2020 | β |
| Prediction of treatment resistance in obsessive compulsive disorder patients based on EEG complexity as a biomarker. | AltuΔlu TB et al. | β | 2020 | β |
| The anterior limb of the internal capsule: Anatomy, function, and dysfunction. | Mithani K et al. | β | 2020 | β |
| Trichotillomania is more related to Tourette disorder than to obsessive-compulsive disorder. | Lamothe H et al. | β | 2020 | β |
| Use of EEG for Predicting Treatment Response to Transcranial Magnetic Stimulation in Obsessive Compulsive Disorder. | Metin SZ et al. | β | 2020 | β |
| Antipsychotic augmentation in the treatment of obsessive-compulsive disorder. | Thamby A et al. | β | 2019 | β |
| A systematic review of the use of risperidone, paliperidone and aripiprazole as augmenting agents for obsessive-compulsive disorder. | Brakoulias V et al. | β | 2019 | β |
| Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: A network meta-analysis. | Zhou DD et al. | β | 2019 | β |
| Celecoxib potentiates the antianxiety and anticompulsive-like activity of fluoxetine against chronic unpredictable mild stress in experimental animals. | Garabadu D et al. | β | 2019 | β |
| Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study. | Zheng H et al. | β | 2019 | β |
| Comparative efficacy and tolerability of antipsychotics as augmentations in adults with treatment-resistant obsessive-compulsive disorder: A network meta-analysis. | Zhou DD et al. | β | 2019 | β |
| Electrophysiological and imaging evidence of sustained inhibition in limbic and frontal networks following deep brain stimulation for treatment refractory obsessive compulsive disorder. | Park HR et al. | β | 2019 | β |
| Fluvoxamine combination therapy with tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial. | Shalbafan M et al. | β | 2019 | β |
| Level of Insight in Patients With Obsessive-Compulsive Disorder: An Exploratory Comparative Study Between Patients With "Good Insight" and "Poor Insight". | de Avila RCS et al. | β | 2019 | β |
| Obsessive-compulsive disorder. | Stein DJ et al. | β | 2019 | β |
| Obsessive-compulsive symptoms in schizophrenia: a review. | Grover S et al. | β | 2019 | β |
| Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD). | Del Casale A et al. | β | 2019 | β |
| The Endocannabinoid System: A New Treatment Target for Obsessive Compulsive Disorder? | Kayser RR et al. | β | 2019 | β |
| Tourette disorder and other tic disorders. | Deeb W et al. | β | 2019 | β |
| A Psycho-Behavioral Perspective on Modelling Obsessive-Compulsive Disorder (OCD) in Animals: The Role of Context. | Wolmarans W et al. | β | 2018 | β |
| Are Mentalizing Abilities and Insight Related to the Severity of Obsessive-Compulsive Disorder. | Δ°nanΓ§ L et al. | β | 2018 | β |
| Aripiprazole as an adjuvant treatment for obsessive and compulsive symptoms in manic phase of bipolar disorder: A randomized, double-blind, placebo-controlled clinical trial. | Sahraian A et al. | β | 2018 | β |
| Association of serotonin receptor 2a haplotypes with obsessive-compulsive disorder and its treatment response in Iranian patients: a genetic and pharmacogenetic study. | Sina M et al. | β | 2018 | β |
| A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy. | Albert U et al. | β | 2018 | β |
| Bridging the Great Divide: What Can Neurology Learn From Psychiatry? | Perez DL et al. | β | 2018 | β |
| Combining Drug and Psychological Treatments for Obsessive- Compulsive Disorder: What is the Evidence, When and for Whom. | Albert U et al. | β | 2018 | β |
| Could dietary glutamate be contributing to the symptoms of obsessive-compulsive disorder? | Holton KF et al. | β | 2018 | β |
| Critical Review of the Use of Second-Generation Antipsychotics in Obsessive-Compulsive and Related Disorders. | Kim D et al. | β | 2018 | β |
| Effectiveness of Electroconvulsive Therapy (ECT) in Parkinsonian Symptoms: A Case Series. | Grover S et al. | β | 2018 | β |
| Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [<sup>11</sup> C]DASB PET study. | Lee J et al. | β | 2018 | β |
| Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - Findings from a European multicenter study. | Dold M et al. | β | 2018 | β |
| Mapping Compulsivity in the DSM-5 Obsessive Compulsive and Related Disorders: Cognitive Domains, Neural Circuitry, and Treatment. | Fineberg NA et al. | β | 2018 | β |
| Monoamine abnormalities in the SAPAP3 knockout model of obsessive-compulsive disorder-related behaviour. | Wood J et al. | β | 2018 | β |
| Neuroscientifically Informed Formulation and Treatment Planning for Patients With Obsessive-Compulsive Disorder: A Review. | Dougherty DD et al. | β | 2018 | β |
| Novel ensemble method for the prediction of response to fluvoxamine treatment of obsessive-compulsive disorder. | Hasanpour H et al. | β | 2018 | β |
| Personality measures after gamma ventral capsulotomy in intractable OCD. | Paiva RR et al. | β | 2018 | β |
| Pharmacotherapy of Obsessive-Compulsive Disorder During Breastfeeding. | Uguz F | β | 2018 | β |
| Promising Treatments for Obsessive-Compulsive Disorder: A Call for Additional Research. | M Koran L et al. | β | 2018 | β |
| Systematic review of co-occurring OCD and TD: Evidence for a tic-related OCD subtype? | Kloft L et al. | β | 2018 | β |
| Tic-related obsessiveβcompulsive disorder | Pringsheim T et al. | β | 2018 | β |
| Transcranial magnetic stimulation in obsessive-compulsive disorder: A focus on network mechanisms and state dependence. | Cocchi L et al. | β | 2018 | β |
| Transition from Obsession to Delusion in Schizo-obsessive Disorder: A Case Report and Literature Overview. | Scotti-Muzzi E et al. | β | 2018 | β |
| Anatomical relationships between serotonin 5-HT2A and dopamine D2 receptors in living human brain. | Ishii T et al. | β | 2017 | β |
| A trans-diagnostic perspective on obsessive-compulsive disorder. | Gillan CM et al. | β | 2017 | β |
| Current and emerging brain applications of MR-guided focused ultrasound. | Meng Y et al. | β | 2017 | β |
| Detrimental effect of clomipramine on hippocampus-dependent learning in an animal model of obsessive-compulsive disorder induced by sensitization with d2/d3 agonist quinpirole. | Hatalova H et al. | β | 2017 | β |
| Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder. | Costa DLDC et al. | β | 2017 | β |
| Divergent Structural Responses to Pharmacological Interventions in Orbitofronto-Striato-Thalamic and Premotor Circuits in Obsessive-Compulsive Disorder. | Lv Q et al. | β | 2017 | β |
| Effects of Anterior Capsulotomy on Decision Making in Patients with Refractory Obsessive-Compulsive Disorder. | Zhang C et al. | β | 2017 | β |
| Efficacy of Transcranial Direct Current Stimulation in the Treatment: Resistant Patients who Suffer from Severe Obsessive-compulsive Disorder. | Najafi K et al. | β | 2017 | β |
| Inflammation in the Neurocircuitry of Obsessive-Compulsive Disorder. | Attwells S et al. | β | 2017 | β |
| Italian prescribing patterns in obsessive-compulsive disorder. | Marazziti D et al. | β | 2017 | β |
| L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. | Arabzadeh S et al. | β | 2017 | β |
| Multidimensional Approaches for A Case of Severe Adult Obsessive - Compulsive Disorder. | Shi Z et al. | β | 2017 | β |
| [New developments in the psychotherapeutic and pharmacological treatment of pediatric obsessivecompulsive disorder]. | Vloet TD et al. | β | 2017 | β |
| Pharmacotherapy for obsessive-compulsive disorder (OCD): predicting response and moving beyond serotonin re-uptake inhibitors. | Brakoulias V et al. | β | 2017 | β |
| Rodent models of obsessive compulsive disorder: Evaluating validity to interpret emerging neurobiology. | Zike I et al. | β | 2017 | β |
| Schizo-obsessive spectrum disorders: an update. | Scotti-Muzzi E et al. | β | 2017 | β |
| The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia. | Einoch R et al. | β | 2017 | β |
| Altered cognitive response to serotonin challenge as a candidate endophenotype for obsessive-compulsive disorder. | Lochner C et al. | β | 2016 | β |
| Calcium Signaling Pathway Is Associated with the Long-Term Clinical Response to Selective Serotonin Reuptake Inhibitors (SSRI) and SSRI with Antipsychotics in Patients with Obsessive-Compulsive Disorder. | Umehara H et al. | β | 2016 | β |
| Challenges in Managing Treatment-Refractory Obsessive-Compulsive Disorder and Tourette's Syndrome. | Lizano P et al. | β | 2016 | β |
| Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India. | Hegde A et al. | β | 2016 | β |
| Integrative Medicine Approach to Pediatric Obsessive-Compulsive Disorder and Anxiety: A Case Report. | Couture DC et al. | β | 2016 | β |
| Lamotrigine Augmentation in Treatment-Resistant Pediatric Obsessive-Compulsive Disorder with a 16 Month Follow-up. | Naguy A et al. | β | 2016 | β |
| Lamotrigine Augmentation Versus Placebo in Serotonin Reuptake Inhibitors-Resistant Obsessive-Compulsive Disorder: A Randomized Controlled Trial. | Khalkhali M et al. | β | 2016 | β |
| OCD is associated with an altered association between sensorimotor gating and cortical and subcortical 5-HT1b receptor binding. | Pittenger C et al. | β | 2016 | β |
| Pharmacoepidemiology of obsessive-compulsive disorder: A Swedish nationwide cohort study. | Isomura K et al. | β | 2016 | β |
| Pharmacotherapy for obsessive compulsive disorder in clinical practice - Data of 842 inpatients from the International AMSP Project between 1994 and 2012. | Poppe C et al. | β | 2016 | β |
| Prazosin addition to fluvoxamine: A preclinical study and open clinical trial in OCD. | Feenstra MGP et al. | β | 2016 | β |
| Predictors of response to serotonin reuptake inhibitors in obsessive-compulsive disorder. | Hazari N et al. | β | 2016 | β |
| Prevalence of antipsychotic prescriptions among patients with anxiety disorders treated in inpatient and outpatient psychiatric settings. | Weber SR et al. | β | 2016 | β |
| Psychopharmacological treatment differences in autogenous and reactive obsessions: A retrospective chart review. | Batmaz S et al. | β | 2016 | β |
| Riluzole in augmentation of fluvoxamine for moderate to severe obsessive-compulsive disorder: Randomized, double-blind, placebo-controlled study. | Emamzadehfard S et al. | β | 2016 | β |
| Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder. | Varigonda AL et al. | β | 2016 | β |
| Treatment-refractory obsessive compulsive disorder. | Atmaca M | β | 2016 | β |
| Treatment-refractory Tourette Syndrome. | Kious BM et al. | β | 2016 | β |
| Ziprasidone Augmentation in an Adolescent with Obsessive Compulsive Disorder: A Case Report. | Demirkaya SK et al. | β | 2016 | β |
| A direct GABAergic output from the basal ganglia to frontal cortex. | Saunders A et al. | β | 2015 | β |
| Amisulpride as add-on treatment for resistant obsessive-compulsive disorder: retrospective case series. | Miodownik C et al. | β | 2015 | β |
| Animal models of obsessive-compulsive disorder: utility and limitations. | Alonso P et al. | β | 2015 | β |
| Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials. | Dold M et al. | β | 2015 | β |
| Are 5-HT3 antagonists effective in obsessive-compulsive disorder? A systematic review of literature. | Serata D et al. | β | 2015 | β |
| Aripiprazole versus quetiapine in treatment-resistant obsessive-compulsive disorder: a double-blind clinical trial. | Shoja Shafti S et al. | β | 2015 | β |
| Assessment and management of treatment-refractory obsessive-compulsive disorder in children. | Bloch MH et al. | β | 2015 | β |
| Augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: What moderates improvement? | Wheaton MG et al. | β | 2015 | β |
| Cigarette smoking in obsessive-compulsive disorder and unaffected parents of OCD patients. | Abramovitch A et al. | β | 2015 | β |
| Comorbidity Between Attention Deficit/Hyperactivity Disorder and Obsessive-Compulsive Disorder Across the Lifespan: A Systematic and Critical Review. | Abramovitch A et al. | β | 2015 | β |
| Cross-disorder genome-wide analyses suggest a complex genetic relationship between Tourette's syndrome and OCD. | Yu D et al. | β | 2015 | β |
| Exposure and response prevention helps adults with obsessive-compulsive disorder who do not respond to pharmacological augmentation strategies. | McLean CP et al. | β | 2015 | β |
| Glutamate modulators in the treatment of obsessive-compulsive disorder. | Pittenger C | β | 2015 | β |
| Glutamatergic agents for OCD and related disorders. | Pittenger C | β | 2015 | β |
| How resistant is 'treatment-resistant' obsessive-compulsive disorder in youth? | Krebs G et al. | β | 2015 | β |
| In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept. | Rodriguez CI et al. | β | 2015 | β |
| Neuroimaging of psychotherapy for obsessive-compulsive disorder: A systematic review. | Thorsen AL et al. | β | 2015 | β |
| No association between the COMT Val158Met polymorphism and the long-term clinical response in obsessive-compulsive disorder in the Japanese population. | Umehara H et al. | β | 2015 | β |
| Obsessive-compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults. | Fineberg NA et al. | β | 2015 | β |
| Obsessive-compulsive disorders and anxiety disorders: A comparison of personality and emotionality patterns. | Pelissolo A et al. | β | 2015 | β |
| Pharmacotherapy of obsessive-compulsive disorder during pregnancy: a clinical approach. | Uguz F | β | 2015 | β |
| Plasma cytokine abnormalities in drug-naΓ―ve, comorbidity-free obsessive-compulsive disorder. | Rao NP et al. | β | 2015 | β |
| Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. | Pittenger C et al. | β | 2015 | β |
| Risperidone as monotherapy for a patient with obsessive compulsive disorder comorbid with schizoaffective disorder: a case report. | Chiou YJ et al. | β | 2015 | β |
| Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder. | Foa EB et al. | β | 2015 | β |
| Tics Moderate Sertraline, but Not Cognitive-Behavior Therapy Response in Pediatric Obsessive-Compulsive Disorder Patients Who Do Not Respond to Cognitive-Behavior Therapy. | Skarphedinsson G et al. | β | 2015 | β |
| Transcranial direct current stimulation in obsessive-compulsive disorder: emerging clinical evidence and considerations for optimal montage of electrodes. | SenΓ§o NM et al. | β | 2015 | β |
| Transcranial direct current stimulation in psychiatric disorders. | Tortella G et al. | β | 2015 | β |
| Visuospatial Memory Improvement after Gamma Ventral Capsulotomy in Treatment Refractory Obsessive-Compulsive Disorder Patients. | Batistuzzo MC et al. | β | 2015 | β |
| Animal models of obsessive-compulsive spectrum disorders. | Camilla d'Angelo LS et al. | β | 2014 | β |
| Are trauma and dissociation related to treatment resistance in patients with obsessive-compulsive disorder? | Semiz UB et al. | β | 2014 | β |
| A study of poor insight in social anxiety disorder. | Vigne P et al. | β | 2014 | β |
| Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. | Katzman MA et al. | β | 2014 | β |
| Clinical Features of Tourette Syndrome and Tic Disorders. | Leckman JF et al. | β | 2014 | β |
| Clinically relevant interactions between newer antidepressants and second-generation antipsychotics. | Spina E et al. | β | 2014 | β |
| Clinical practice: Obsessive-compulsive disorder. | Grant JE | β | 2014 | β |
| Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment. | Zink M | β | 2014 | β |
| D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis. | Ducasse D et al. | β | 2014 | β |
| Deep brain stimulation for obsessive-compulsive disorder: a systematic review and meta-analysis. | Kisely S et al. | β | 2014 | β |
| Effect of aripiprazole augmentation for treatment-resistant somatoform disorder: a case series. | Nagoshi Y et al. | β | 2014 | β |
| Emerging drugs to treat obsessive-compulsive disorder. | Pallanti S et al. | β | 2014 | β |
| Goal-directed learning and obsessive-compulsive disorder. | Gillan CM et al. | β | 2014 | β |
| Management of obsessive-compulsive disorder. | Seibell PJ et al. | β | 2014 | β |
| Obsessive-compulsive disorder for ICD-11: proposed changes to the diagnostic guidelines and specifiers. | Simpson HB et al. | β | 2014 | β |
| Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation. | Pallanti S et al. | β | 2014 | β |
| Perceptual properties of obsessive thoughts are associated with low insight in obsessive-compulsive disorder. | Moritz S et al. | β | 2014 | β |
| Performance of compulsive behavior in rats is not a unitary phenomenon - validation of separate functional components in compulsive checking behavior. | Tucci MC et al. | β | 2014 | β |
| Pharmacological treatment of obsessive-compulsive disorder. | Pittenger C et al. | β | 2014 | β |
| Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. | Van Ameringen M et al. | β | 2014 | β |
| Pharmacologic treatment of obsessive-compulsive disorder comorbidity. | Pallanti S et al. | β | 2014 | β |
| Polypharmacy with antidepressants in children and adolescents. | DΓaz-Caneja CM et al. | β | 2014 | β |
| Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature. | Fonseka TM et al. | β | 2014 | β |
| Separate mechanisms for development and performance of compulsive checking in the quinpirole sensitization rat model of obsessive-compulsive disorder (OCD). | Tucci MC et al. | β | 2014 | β |
| The impact of comorbid body dysmorphic disorder on the response to sequential pharmacological trials for obsessive-compulsive disorder. | Diniz JB et al. | β | 2014 | β |
| The role of the brain-derived neurotrophic factor SNP rs2883187 in the phenotypic expression of obsessive-compulsive disorder. | TΓΌkel R et al. | β | 2014 | β |
| Tic-related obsessive-compulsive disorder (OCD): phenomenology and treatment outcome in the Pediatric OCD Treatment Study II. | Conelea CA et al. | β | 2014 | β |
| Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. | Afshar H et al. | β | 2014 | β |
| Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study. | Masi G et al. | β | 2013 | β |
| Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. | Dold M et al. | β | 2013 | β |
| Augmentation strategies in obsessive-compulsive disorder. | Arumugham SS et al. | β | 2013 | β |
| Clinical assessment of Tourette syndrome and tic disorders. | Cohen SC et al. | β | 2013 | β |
| Clinical pharmacology of comorbid obsessive-compulsive disorder in Tourette syndrome. | Neri V et al. | β | 2013 | β |
| Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial. | Simpson HB et al. | β | 2013 | β |
| Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors. | Schirmbeck F et al. | β | 2013 | β |
| COMT Val158Met polymorphism and executive functions in obsessive-compulsive disorder. | TΓΌkel R et al. | β | 2013 | β |
| Differential effects of antipsychotic agents on obsessive-compulsive symptoms in schizophrenia: a longitudinal study. | Schirmbeck F et al. | β | 2013 | β |
| Effects of mood stabilizers on marble-burying behavior in mice: involvement of GABAergic system. | Egashira N et al. | β | 2013 | β |
| Is there a Role for Immunological Mechanisms in Etiopathogenesis of Obsessive Compulsive Disorder? | Rao NP et al. | β | 2013 | β |
| Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. | Ghaleiha A et al. | β | 2013 | β |
| Metabolic and toxicological considerations for obsessive-compulsive disorder drug therapy. | Sayyah M et al. | β | 2013 | β |
| Metabolic syndrome and obsessive-compulsive disorder: a naturalistic Italian study. | Albert U et al. | β | 2013 | β |
| Obsessive-compulsive disorders. | Thomsen PH | β | 2013 | β |
| Pharmacotherapy response and regional cerebral blood flow characteristics in patients with obsessive-compulsive disorder. | Wen SL et al. | β | 2013 | β |
| Practice parameter for the assessment and treatment of children and adolescents with tic disorders. | Murphy TK et al. | β | 2013 | β |
| Prediction of treatment response and the effect of independent component neurofeedback in obsessive-compulsive disorder: a randomized, sham-controlled, double-blind study. | KopΕivovΓ‘ J et al. | β | 2013 | β |
| Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. | Rodriguez CI et al. | β | 2013 | β |
| The comparison of pre- and post-treatment (99m)Tc HMPAO brain SPECT images in patients with obsessive-compulsive disorder. | KaradaΔ F et al. | β | 2013 | β |
| [The obsessive compulsive disorder]. | Flores Alves Dos Santos J et al. | β | 2013 | β |
| Treating refractory obsessive-compulsive disorder: what to do when conventional treatment fails? | Franz AP et al. | β | 2013 | β |
| A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder. | Stein DJ et al. | β | 2012 | β |
| A case of severe adolescent obsessive-compulsive disorder treated with inpatient hospitalization, risperidone and sertraline. | Nguyen ML et al. | β | 2012 | β |
| Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series. | Higuma H et al. | β | 2012 | β |
| Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex. | Danovich L et al. | β | 2012 | β |
| Circadian rhythms in obsessive-compulsive disorder. | Lange KW et al. | β | 2012 | β |
| Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. | Schirmbeck F et al. | β | 2012 | β |
| Cognitive therapy versus fluvoxamine as a second-step treatment in obsessive-compulsive disorder nonresponsive to first-step behavior therapy. | van Balkom AJ et al. | β | 2012 | β |
| D1 and D2 dopamine receptor antagonists decrease behavioral bout duration, without altering the bout's repeated behavioral components, in a naturalistic model of repetitive and compulsive behavior. | Hoffman KL et al. | β | 2012 | β |
| Effectiveness of cognitive-behavioral therapy addition to pharmacotherapy in resistant obsessive-compulsive disorder: a multicenter study. | Albert U et al. | β | 2012 | β |
| Effects of aripiprazole augmentation in treatment-resistant obsessive-compulsive disorder (a double blind clinical trial). | Sayyah M et al. | β | 2012 | β |
| Effects of ketamine in treatment-refractory obsessive-compulsive disorder. | Bloch MH et al. | β | 2012 | β |
| Error-related negativity and tic history in pediatric obsessive-compulsive disorder. | Hanna GL et al. | β | 2012 | β |
| Lamotrigine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. | Bruno A et al. | β | 2012 | β |
| Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry. | Robbins TW et al. | β | 2012 | β |
| Neurotrophic factors in obsessive-compulsive disorder. | Fontenelle LF et al. | β | 2012 | β |
| Obsessive compulsive disorder. | Soomro GM | β | 2012 | β |
| Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. | β | β | 2012 | β |
| [Psychotherapeutic and pharmacological treatment of pediatric obsessive-compulsive disorder]. | Vloet TD et al. | β | 2012 | β |
| Real-time fMRI biofeedback targeting the orbitofrontal cortex for contamination anxiety. | Hampson M et al. | β | 2012 | β |
| The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. | Wu K et al. | β | 2012 | β |
| A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder. | Diniz JB et al. | β | 2011 | β |
| Animal models of obsessive compulsive disorder: recent findings and future directions. | Hoffman KL | β | 2011 | β |
| Antipsychotics in anxiety disorders: an oxymoron or a reflection of non-adequate nomenclature? | Zohar J et al. | β | 2011 | β |
| Effect of aripiprazole augmentation of serotonin reuptake inhibitors or clomipramine in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. | Muscatello MR et al. | β | 2011 | β |
| European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. | Roessner V et al. | β | 2011 | β |
| [Evidence-based pharmacotherapy and other somatic treatment approaches for obsessive-compulsive disorder: state of the art]. | Kordon A et al. | β | 2011 | β |
| Evidence-based pharmacotherapy for pediatric obsessive-compulsive disorder and chronic tic disorders. | De Nadai AS et al. | β | 2011 | β |
| Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. | Pittenger C et al. | β | 2011 | β |
| Obsessive-compulsive disorder comorbidity: clinical assessment and therapeutic implications. | Pallanti S et al. | β | 2011 | β |
| Obsessive-compulsive spectrum disorders: still in search of the concept-affirming boundaries. | Starcevic V et al. | β | 2011 | β |
| Pharmacological management of treatment-resistant obsessive-compulsive disorder. | Abudy A et al. | β | 2011 | β |
| Pharmacotherapy of anxiety disorders: a critical review. | Koen N et al. | β | 2011 | β |
| Predictors of early adulthood quality of life in children with obsessive-compulsive disorder. | Palermo SD et al. | β | 2011 | β |
| Psychotherapy and medication management strategies for obsessive-compulsive disorder. | Walsh KH et al. | β | 2011 | β |
| Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. | Zuddas A et al. | β | 2011 | β |
| SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patients. | Silver H et al. | β | 2011 | β |
| The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study. | Selvi Y et al. | β | 2011 | β |
| The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment. | Danovich L et al. | β | 2011 | β |
| The neurobiology of repetitive behavior: β¦and men. | Langen M et al. | β | 2011 | β |
| Translational approaches to obsessive-compulsive disorder: from animal models to clinical treatment. | Fineberg NA et al. | β | 2011 | β |
| Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder. | Uzun O et al. | β | 2010 | β |
| Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. | Masi G et al. | β | 2010 | β |
| Drug treatment of obsessive-compulsive disorder. | Kellner M | β | 2010 | β |
| Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder. | Dell'Osso B et al. | β | 2010 | β |
| High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey. | Pampaloni I et al. | β | 2010 | β |
| Impaired visuospatial associative memory and attention in obsessive compulsive disorder but no evidence for differential dopaminergic modulation. | Morein-Zamir S et al. | β | 2010 | β |
| Intravenous anti-obsessive agents: a review. | Ravindran LN et al. | β | 2010 | β |
| Management of tics and Tourette's disorder: an update. | Bestha DP et al. | β | 2010 | β |
| Multiple pathways to functional impairment in obsessive-compulsive disorder. | Markarian Y et al. | β | 2010 | β |
| Obsessions and compulsions in children with Asperger's syndrome or high-functioning autism: a case-control study. | Mack H et al. | β | 2010 | β |
| Obsessive-compulsive disorder: a review of the diagnostic criteria and possible subtypes and dimensional specifiers for DSM-V. | Leckman JF et al. | β | 2010 | β |
| Pharmacological treatment of obsessive-compulsive disorder. | Simpson HB | β | 2010 | β |
| Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review. | Fineberg NA et al. | β | 2010 | β |
| Quetiapine: novel uses in the treatment of depressive and anxiety disorders. | Ravindran AV et al. | β | 2010 | β |
| Quetiapine versus clomipramine in the augmentation of selective serotonin reuptake inhibitors for the treatment of obsessive-compulsive disorder: a randomized, open-label trial. | Diniz JB et al. | β | 2010 | β |
| Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. | Delorme R et al. | β | 2010 | β |
| Repetitive behaviours in patients with Gilles de la Tourette syndrome: tics, compulsions, or both? | Worbe Y et al. | β | 2010 | β |
| Role of dopamine in the pathophysiology and treatment of obsessive-compulsive disorder. | Koo MS et al. | β | 2010 | β |
| Second-generation antipsychotics for obsessive compulsive disorder. | Komossa K et al. | β | 2010 | β |
| Should an obsessive-compulsive spectrum grouping of disorders be included in DSM-V? | Phillips KA et al. | β | 2010 | β |
| The Genetics of Obsessive-Compulsive Disorder. | Bloch MH et al. | β | 2010 | β |
| The role of comorbid disruptive behavior in the clinical expression of pediatric obsessive-compulsive disorder. | Storch EA et al. | β | 2010 | β |
| Treatment of pediatric obsessive-compulsive disorder: a review. | Mancuso E et al. | β | 2010 | β |
| Treatment-resistant Obsessive-compulsive Disorder in Young People: Assessment and Treatment Strategies. | Krebs G et al. | β | 2010 | β |
| Treatment strategies for obsessive-compulsive disorder. | Marazziti D et al. | β | 2010 | β |
| A cytokine study in children and adolescents with Tourette's disorder. | Gabbay V et al. | β | 2009 | β |
| Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. | Goodwin G et al. | β | 2009 | β |
| Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. | Pessina E et al. | β | 2009 | β |
| Aripiprazole treatment in an adolescent patient with chronic motor tic disorder and treatment-resistant obsessive-compulsive disorder. | Lai CH | β | 2009 | β |
| Artificial neural network model for the prediction of obsessive-compulsive disorder treatment response. | Salomoni G et al. | β | 2009 | β |
| Assessing the validity of current mouse genetic models of obsessive-compulsive disorder. | Wang L et al. | β | 2009 | β |
| Children with obsessive-compulsive disorder: are they just "little adults"? | Kalra SK et al. | β | 2009 | β |
| Clinical course of Tourette syndrome. | Bloch MH et al. | β | 2009 | β |
| Electroacupuncture for refractory obsessive-compulsive disorder: a pilot waitlist-controlled trial. | Zhang ZJ et al. | β | 2009 | β |
| Epidemiology and management of anxiety in patients with bipolar disorder. | Kauer-Sant'Anna M et al. | β | 2009 | β |
| High-dose duloxetine for treatment-resistant obsessive-compulsive disorder: a case report with sustained full remission. | Yeh YW et al. | β | 2009 | β |
| Management of schizophrenia with obsessive-compulsive features. | Hwang MY et al. | β | 2009 | β |
| Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia. | Chertkow Y et al. | β | 2009 | β |
| Neuroanatomical, neurochemical, and neurodevelopmental basis of obsessive-compulsive symptoms in schizophrenia. | Venkatasubramanian G et al. | β | 2009 | β |
| New pharmacotherapeutic approaches to obsessive-compulsive disorder. | Figee M et al. | β | 2009 | β |
| Obsessive-compulsive disorder. | Abramowitz JS et al. | β | 2009 | β |
| Obsessive-compulsive disorder: diagnostic and treatment issues. | Stein DJ et al. | β | 2009 | β |
| Obsessive-compulsive spectrum disorders: a review of the evidence-based treatments. | Ravindran AV et al. | β | 2009 | β |
| Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study. | Pallanti S et al. | β | 2009 | β |
| Paliperidone for treatment of obsessive compulsive resistant symptoms in schizophrenia: a case report. | Angelucci F et al. | β | 2009 | β |
| Predictors of early adult outcomes in pediatric-onset obsessive-compulsive disorder. | Bloch MH et al. | β | 2009 | β |
| Psychiatric comorbidities and schizophrenia. | Buckley PF et al. | β | 2009 | β |
| Sequential allocation to balance prognostic factors in a psychiatric clinical trial. | Fossaluza V et al. | β | 2009 | β |
| Successful aripiprazole augmentation in a child with drug-resistant obsessive-compulsive disorder. | OztΓΌrk M et al. | β | 2009 | β |
| Symptom dimensions and subtypes of obsessive-compulsive disorder: a developmental perspective. | Leckman JF et al. | β | 2009 | β |
| The 5-HT2 receptor profiles of antipsychotics in the pathogenesis of obsessive-compulsive symptoms in schizophrenia. | Kim SW et al. | β | 2009 | β |
| The Pediatric Obsessive-Compulsive Disorder Treatment Study II: rationale, design and methods. | Freeman JB et al. | β | 2009 | β |
| Tourette's syndrome, trichotillomania, and obsessive-compulsive disorder: how closely are they related? | FerrΓ£o YA et al. | β | 2009 | β |
| 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. | Maina G et al. | β | 2008 | β |
| Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study. | Kim SW et al. | β | 2008 | β |
| A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. | Simpson HB et al. | β | 2008 | β |
| Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report. | Fornaro M et al. | β | 2008 | β |
| Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder. | Sarkar R et al. | β | 2008 | β |
| Aripiprazole augmentation of incomplete treatment response in an adolescent male with obsessive-compulsive disorder. | Storch EA et al. | β | 2008 | β |
| Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms. | Egashira N et al. | β | 2008 | β |
| Association of the serotonin transporter polymorphism and obsessive-compulsive disorder: systematic review. | Bloch MH et al. | β | 2008 | β |
| Clinical implications of insight assessment in obsessive-compulsive disorder. | Alonso P et al. | β | 2008 | β |
| Do all obsessive-compulsive disorder subtypes respond to medication? | Grados M et al. | β | 2008 | β |
| Dose-related exacerbation of obsessive-compulsive symptoms with quetiapine treatment. | Chen CH et al. | β | 2008 | β |
| Effectiveness of aripiprazole in treating obsessive compulsive symptoms. | Yang KC et al. | β | 2008 | β |
| Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. | Marazziti D et al. | β | 2008 | β |
| Emerging treatments for Tourette's disorder. | Bloch MH | β | 2008 | β |
| Eosinophilic meningoencephalitis: psychiatric presentation and treatment. | Hong DS et al. | β | 2008 | β |
| Experimental therapeutics for refractory obsessive-compulsive disorder: translational approaches and new somatic developments. | Berlin HA et al. | β | 2008 | β |
| Neurobiology confirms psychopathology. On the antagonism of psychosis and obsessive-compulsive syndromes. | Zink M et al. | β | 2008 | β |
| Pediatric obsessive-compulsive disorder: management priorities in primary care. | Gilbert AR et al. | β | 2008 | β |
| Quetiapine addition to serotonin reuptake inhibitors in patients with severe obsessive-compulsive disorder: a double-blind, randomized, placebo-controlled study. | Kordon A et al. | β | 2008 | β |
| [Resistant Obsessive Compulsive disorder (ROC): clinical picture, predictive factors and influence of affective temperaments]. | Hantouche EG et al. | β | 2008 | β |
| Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a series of 13 cases, with long-term follow-up. | Pittenger C et al. | β | 2008 | β |
| Serotoninergic mechanisms in the treatment of obsessive-compulsive disorder. | Goddard AW et al. | β | 2008 | β |
| The medical treatment of obsessive-compulsive disorder and anxiety. | Bandelow B | β | 2008 | β |
| Tourette syndrome and obsessive-compulsive disorder. | Lombroso PJ et al. | β | 2008 | β |
| World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. | Bandelow B et al. | β | 2008 | β |
| Addicted to hair pulling? How an alternate model of trichotillomania may improve treatment outcome. | Grant JE et al. | β | 2007 | β |
| An update on the pharmacological treatment of obsessive-compulsive disorder. | Fontenelle LF et al. | β | 2007 | β |
| Compulsive hoarding associated with abortion. | Sockalingam S et al. | β | 2007 | β |
| Issues in the pharmacological treatment of obsessive-compulsive disorder. | Math SB et al. | β | 2007 | β |
| Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia. | Zink M et al. | β | 2007 | β |
| Obsessive-compulsive disorder: an open-label pilot trial of escitalopram. | GalvΓ£o-de Almeida A et al. | β | 2007 | β |
| Obsessive-compulsive spectrum disorders: cross-national and ethnic issues. | Matsunaga H et al. | β | 2007 | β |
| Perospirone augmentation of paroxetine in treatment of refractory obsessive-compulsive disorder with depression. | Otsuka T et al. | β | 2007 | β |
| Recent advances in the understanding and treatment of anxiety disorders. | Shearer SL | β | 2007 | β |
| [Resistance and refractoriness in obsessive-compulsive disorder]. | FerrΓ£o YA et al. | β | 2007 | β |
| Review: antipsychotic augmentation is effective for people with obsessive-convulsive disorder who are receiving, but not responding to, serotonin reuptake inhibitor monotherapy. | Dell'Osso B | β | 2007 | β |
| Successful augmentation with aripiprazole in clomipramine-refractory obsessive-compulsive disorder. | da Rocha FF et al. | β | 2007 | β |
| Tourette syndrome and tic disorders: a decade of progress. | Swain JE et al. | β | 2007 | β |
| Obsessive-compulsive disorder. | Heyman I et al. | β | 2006 | β |
| [Obsessive compulsive disorders]. | β | β | 1993 | β |